Emcure Pharmaceuticals (EMCURE) Aperçu de l'action
Emcure Pharmaceuticals Limited développe, fabrique et commercialise des produits pharmaceutiques dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 5/6 |
| Performances passées | 6/6 |
| Santé financière | 6/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour EMCURE à partir de nos contrôles de risques.
EMCURE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Emcure Pharmaceuticals Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹1,873.90 |
| Plus haut sur 52 semaines | ₹2,048.00 |
| Plus bas sur 52 semaines | ₹1,260.00 |
| Bêta | -0.056 |
| Variation sur 1 mois | 5.09% |
| Variation sur 3 mois | 9.57% |
| Variation sur 1 an | 28.92% |
| Variation sur 3 ans | n/a |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | 37.87% |
Nouvelles et mises à jour récentes
Earnings Beat: Emcure Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, Emcure Pharmaceuticals Limited ( NSE:EMCURE ) just kicked off its latest first-quarter results with...
EMCURE: Governance Shifts And Dividend Plans Will Shape Balanced Outlook
Analysts have lifted the Emcure Pharmaceuticals fair value estimate from ₹1,913.50 to ₹2,039.86, citing updated assumptions that include a slightly different discount rate, revised revenue growth expectations, a higher profit margin outlook, and a lower future P/E multiple in their price target framework. What's in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals has recommended a final dividend of ₹3.60 per equity share of ₹10 each for the financial year ending March 31, 2026, subject to shareholder approval at the AGM.Recent updates
Earnings Beat: Emcure Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, Emcure Pharmaceuticals Limited ( NSE:EMCURE ) just kicked off its latest first-quarter results with...EMCURE: Governance Shifts And Dividend Plans Will Shape Balanced Outlook
Analysts have lifted the Emcure Pharmaceuticals fair value estimate from ₹1,913.50 to ₹2,039.86, citing updated assumptions that include a slightly different discount rate, revised revenue growth expectations, a higher profit margin outlook, and a lower future P/E multiple in their price target framework. What's in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals has recommended a final dividend of ₹3.60 per equity share of ₹10 each for the financial year ending March 31, 2026, subject to shareholder approval at the AGM.EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook
Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook
Analysts have maintained their price target for Emcure Pharmaceuticals at ₹1,795.67, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for keeping their valuation view intact. What's in the News Board meeting scheduled for May 5, 2026, to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final equity dividend, if any (company filing).EMCURE: Upcoming Governance And Roche Agreement Will Shape Balanced Forward Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals slightly higher to around ₹1,796 from about ₹1,795, citing updated assumptions for revenue growth, profit margins and a modestly lower future P/E expectation. What's in the News Emcure signed a distribution agreement with Roche for select nephrology and transplant medicines in India, covering therapies for chronic kidney disease, anemia management, and transplant care, effective April 1, 2026 (Key Developments).EMCURE: Upcoming Governance Decisions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margin and future P/E. This signals that their core view on the stock remains consistent.EMCURE: Weight Management Franchise Will Support Future Upside Potential
Analysts have kept their price target for Emcure Pharmaceuticals steady at ₹1,794.83, citing essentially unchanged assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Emcure plans a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.EMCURE: Weight Management Launch Will Underpin Future Shareholder Value Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794.83 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, which together support an unchanged price target narrative. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).EMCURE: Weight Management Launch Will Support Stronger Long Term Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals higher from ₹1,688.50 to about ₹1,794.83, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E, which together support a slightly richer valuation framework. What's in the News Board meeting scheduled for Feb 4, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Here's Why We Think Emcure Pharmaceuticals (NSE:EMCURE) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...EMCURE: Weight Management Launch And Alliance Will Shape Balanced Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals from ₹1,652.50 to ₹1,688.50, reflecting updated assumptions related to revenue growth, profit margins and a slightly lower future P/E multiple. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Emcure Pharmaceuticals Limited ( NSE:EMCURE ) last week reported its latest quarterly results, which makes it a good...These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Expansion In Chronic Therapies And Emerging Markets Will Thrive
Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report
The investors in Emcure Pharmaceuticals Limited 's ( NSE:EMCURE ) will be rubbing their hands together with glee today...Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark
Emcure Pharmaceuticals Limited's ( NSE:EMCURE ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...Emcure Pharmaceuticals Limited (NSE:EMCURE) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
The Emcure Pharmaceuticals Limited ( NSE:EMCURE ) share price has fared very poorly over the last month, falling by a...We Think Emcure Pharmaceuticals (NSE:EMCURE) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Rendement pour les actionnaires
| EMCURE | IN Pharmaceuticals | IN Marché | |
|---|---|---|---|
| 7D | -6.1% | -0.3% | -0.4% |
| 1Y | 28.9% | 16.1% | 4.6% |
Rendement vs Industrie: EMCURE a dépassé le secteur Indian Pharmaceuticals qui a rapporté 16.1 % au cours de l'année écoulée.
Rendement vs marché: EMCURE a dépassé le marché Indian qui a rapporté 4.6 % au cours de l'année écoulée.
Volatilité des prix
| EMCURE volatility | |
|---|---|
| EMCURE Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Cours de l'action stable: EMCURE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de EMCURE ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1981 | 6,731 | Satish Mehta | www.emcure.com |
Emcure Pharmaceuticals Limited développe, fabrique et commercialise des produits pharmaceutiques dans le monde entier. Elle propose des produits dans divers domaines thérapeutiques, tels que la gynécologie, les maladies cardiovasculaires, les anti-infectieux, les antiviraux contre le VIH, les maladies respiratoires, les maladies gastro-intestinales, les douleurs et les analgésiques, les maladies du sang, l'oncologie/les antinéoplasiques, les maladies diabétiques, les hormones, la neurologie/le système nerveux central, la dermatologie et d'autres domaines, ainsi que les vitamines, les minéraux et les nutriments. La société développe également des produits sur différentes plateformes, notamment des molécules chirales, des API complexes, des médicaments oraux, des produits à base de fer, des produits photochimiques, des produits injectables liposomaux et lyophilisés, des médicaments très puissants, des produits biothérapeutiques et de nouveaux systèmes d'administration de médicaments.
Emcure Pharmaceuticals Limited Résumé des fondamentaux
| EMCURE statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹355.27b |
| Bénéfices(TTM) | ₹10.11b |
| Recettes(TTM) | ₹96.83b |
Le site EMCURE est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| EMCURE compte de résultat (TTM) | |
|---|---|
| Recettes | ₹96.83b |
| Coût des recettes | ₹39.28b |
| Marge brute | ₹57.55b |
| Autres dépenses | ₹47.44b |
| Les revenus | ₹10.11b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 53.35 |
| Marge brute | 59.43% |
| Marge bénéficiaire nette | 10.44% |
| Ratio dettes/capitaux propres | 30.6% |
Quelles ont été les performances à long terme de EMCURE?
Voir les performances historiques et les comparaisonsDividendes
Le site EMCURE verse-t-il des dividendes fiables ?
Voir EMCURE l'historique des dividendes et les indices de référence| Emcure Pharmaceuticals dates des dividendes | |
|---|---|
| Date ex-dividende | Sep 04 2026 |
| Date de paiement du dividende | Oct 21 2026 |
| Jours jusqu'au dividende Ex | 17 days |
| Jours jusqu'à la date de paiement du dividende | 64 days |
Le site EMCURE verse-t-il des dividendes fiables ?
Voir EMCURE l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/17 21:18 |
| Cours de l'action en fin de journée | 2026/08/17 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Emcure Pharmaceuticals Limited est couverte par 11 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| null null | BOB Capital Markets Ltd. |
| Foram Parekh | BOB Capital Markets Ltd. |